This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Chroma Therapeutics.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Chroma Therapeutics Identifier:
First received: August 5, 2010
Last updated: February 14, 2012
Last verified: February 2012
The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.

Condition Intervention Phase
Acute Myeloid Leukemia Drug: CHR-2797 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat

Resource links provided by NLM:

Further study details as provided by Chroma Therapeutics:

Primary Outcome Measures:
  • Safety and Tolerability of extended treatment with tosedostat [ Time Frame: Protocol mandated visits every 12 weeks ]

    Primary outcome will be assessed using the following procedures/data:

    • Physical exams
    • Vital signs
    • Electrocardiography
    • Laboratory parameters (hematology, chemistry, urinalysis)
    • Adverse events
    • Serious adverse events

Secondary Outcome Measures:
  • Efficacy of extended treatment with tosedostat [ Time Frame: Protocol-mandated visits every 12 weeks ]

    The secondary outcome will be assessed using the following parameters:

    • Overall survival
    • Relapse-free survival
    • Event-free survival
    • Clinical responses (Complete Remission, Complete Remission with Incomplete Platelet Recovery, Morphological Leukemia-Free State, Partial Remission, Stable Disease, Progressive Disease) including best response and time to response
    • Duration of clinical responses.

Estimated Enrollment: 30
Study Start Date: June 2010
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tosedostat Drug: CHR-2797
120mg once daily oral for 48 weeks

Detailed Description:

Extension protocol to the OPAL Study (CHR-2797-038).

Study mimics normal clinical practice; few procedures and visits are therefore mandated by the protocol. Timing of bone marrow assessment is also left at the investigator's discretion.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed, informed consent
  • Completion of Visit 11 in the OPAL Study (Month 6 Visit)
  • Investigator's opinion that the subject would benefit from continued therapy with tosedostat.

Exclusion Criteria:

  • Any co-existing medical condition that in the Investigator's opinion will substantially increase the risk associated with the subject's participation in the study
  • Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
  • Administration of any (other) investigational agent within 14 days of entry into TOPAZ.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01180426

United States, California
UCLA Division of Hematology/Oncology
Los Angeles, California, United States, 90095
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109-2800
United States, New Jersey
John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
United States, New York
New York Presbyterian Hospitacl
New York, New York, United States, 10021
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Texas
MD Anderson
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
Chroma Therapeutics
  More Information

Responsible Party: Chroma Therapeutics Identifier: NCT01180426     History of Changes
Other Study ID Numbers: CHR-2797-045
Study First Received: August 5, 2010
Last Updated: February 14, 2012

Keywords provided by Chroma Therapeutics:
Relapse Refractory Acute Myeloid Leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms processed this record on August 16, 2017